Lycopodium Limited
Lycopodium Limited Fundamental Analysis
Lycopodium Limited (LYL.AX) shows moderate financial fundamentals with a PE ratio of 14.78, profit margin of 10.30%, and ROE of 22.89%. The company generates $0.3B in annual revenue with weak year-over-year growth of -3.08%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 54.2/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze LYL.AX's fundamental strength across five key dimensions:
Efficiency Score
ExcellentLYL.AX demonstrates superior asset utilization.
Valuation Score
ExcellentLYL.AX trades at attractive valuation levels.
Growth Score
WeakLYL.AX faces weak or negative growth trends.
Financial Health Score
ExcellentLYL.AX maintains a strong and stable balance sheet.
Profitability Score
ModerateLYL.AX maintains healthy but balanced margins.
Key Financial Metrics
Is LYL.AX Expensive or Cheap?
P/E Ratio
LYL.AX trades at 14.78 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, LYL.AX's PEG of -0.94 indicates potential undervaluation.
Price to Book
The market values Lycopodium Limited at 3.34 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 10.59 times EBITDA. This signals the market has high growth expectations.
How Well Does LYL.AX Make Money?
Net Profit Margin
For every $100 in sales, Lycopodium Limited keeps $10.30 as profit after all expenses.
Operating Margin
Core operations generate 13.50 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $22.89 in profit for every $100 of shareholder equity.
ROA
Lycopodium Limited generates $13.33 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Lycopodium Limited produces operating cash flow of $37.55M, showing steady but balanced cash generation.
Free Cash Flow
Lycopodium Limited produces free cash flow of $34.41M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.87 in free cash annually.
FCF Yield
LYL.AX converts 6.40% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
14.78
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.94
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.34
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.55
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.17
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.30
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.23
vs 25 benchmark
ROA
Return on assets percentage
0.13
vs 25 benchmark
ROCE
Return on capital employed
0.27
vs 25 benchmark
How LYL.AX Stacks Against Its Sector Peers
| Metric | LYL.AX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 14.78 | 25.96 | Better (Cheaper) |
| ROE | 22.89% | 1263.00% | Weak |
| Net Margin | 10.30% | -41827.00% (disorted) | Strong |
| Debt/Equity | 0.17 | 0.79 | Strong (Low Leverage) |
| Current Ratio | 2.30 | 10.05 | Strong Liquidity |
| ROA | 13.33% | -1497918.00% (disorted) | Strong |
LYL.AX outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Lycopodium Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
61.56%
Industry Style: Cyclical, Value, Infrastructure
High GrowthEPS CAGR
257.59%
Industry Style: Cyclical, Value, Infrastructure
High GrowthFCF CAGR
-41.06%
Industry Style: Cyclical, Value, Infrastructure
Declining